Last €7.06 EUR
Change Today -0.04 / -0.56%
Volume 350.0
2CX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:01 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

chemocentryx inc (2CX) Snapshot

Open
€7.13
Previous Close
€7.10
Day High
€7.28
Day Low
€7.06
52 Week High
01/28/15 - €8.30
52 Week Low
10/2/14 - €3.20
Market Cap
306.0M
Average Volume 10 Days
157.3
EPS TTM
--
Shares Outstanding
43.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHEMOCENTRYX INC (2CX)

Related News

No related news articles were found.

chemocentryx inc (2CX) Related Businessweek News

No Related Businessweek News Found

chemocentryx inc (2CX) Details

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe Crohn’s disease; CCX140 that is in Phase II clinical trial for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company’s drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated renal vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for liver diseases. The company was founded in 1997 and is headquartered in Mountain View, California.

60 Employees
Last Reported Date: 03/14/14
Founded in 1997

chemocentryx inc (2CX) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $510.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $372.2K
Chief Medical Officer
Total Annual Compensation: $369.4K
Compensation as of Fiscal Year 2013.

chemocentryx inc (2CX) Key Developments

ChemoCentryx, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 08:00 AM

ChemoCentryx, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 08:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Thomas J. Schall, Founder, Chairman, Chief Executive Officer and President.

ChemoCentryx, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 04:00 PM

ChemoCentryx, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 04:00 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Thomas J. Schall, Founder, Chairman, Chief Executive Officer and President.

ChemoCentryx, Inc. Announces Positive Results in Phase II Diabetic Nephropathy Trial with CCR2 Inhibitor CCX140

ChemoCentryx, Inc. announced positive top-line 52-week data from its Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2. The trial met its primary endpoint by demonstrating that treatment with 5 mg of CCX140 given orally once daily added to a standard of care regimen of angiotensin converting enzyme inhibitor or angiotensin receptor II blocker (ARB) treatment resulted in a statistically significant (p=0.0148) reduction in urinary albumin creatinine ratio (UACR), beyond that achieved with SOC alone. High UACR is known to predict poor renal outcome. The maximum treatment effect (24% reduction) was reached at 12 weeks, and sustained reduction in albuminuria induced by CCX140 relative to SOC alone was observed over the full year, i.e., UACR at each one of the 10 time points over the 52-week treatment period in the patients who received 5 mg CCX140 continuously for 52 weeks, were below those of the SOC alone group. A dose of 10 mg CCX140 per day did not provide more improvement in albuminuria as compared to the 5 mg dose. In addition, estimated glomerular filtration rate (eGFR) changes were assessed. Measuring eGFR is important in assessing long-term kidney function, and provides the basis for Phase III clinical trial registration endpoints. Numerous clinical trials with the current SOC show that these attenuate the slope of decline of eGFR, and that this translates into a beneficial effect on clinical outcome parameters such as time to dialysis, with chronic multi-year treatment. Treatment with CCX140 improved the eGFR profile. Initial analysis showed that after an acute effect in eGFR in the CCX140 treatment groups in the first 12 weeks, there was a sustained attenuation in the slope of annual decline in eGFR. Such eGFR profiles have been associated with successful long-term clinical benefit in kidney outcomes with approved diabetic nephropathy drugs. The treatment group receiving 5 mg of CCX140 in addition to SOC showed an attenuated annual slope decline of 1.3 mL/min/1.73 m2, compared to SOC alone group, 2.3 mL/min/1.73 m2. The magnitude of slope improvement seen for CCX140 is consistent with drugs that have been previously approved for diabetic nephropathy. CCX140 did not affect systemic blood pressure, suggesting that the beneficial effect of CCX140 is mediated locally in the kidney micro-environment, possibly through a beneficial reduction in renal inflammation. CCX140 appeared to be well tolerated with a low overall dropout rate over the 52-week treatment period. No safety issues were observed that would prevent further clinical development of CCX140 in diabetic nephropathy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
2CX:GR €7.06 EUR -0.04

2CX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Idec Inc $425.61 USD +11.48
Bristol-Myers Squibb Co $66.05 USD +0.38
Incyte Corp $91.97 USD +4.06
Takeda Pharmaceutical Co Ltd ¥6,516 JPY +126.00
Teva Pharmaceutical Industries Ltd $56.51 USD -0.05
View Industry Companies
 

Industry Analysis

2CX

Industry Average

Valuation 2CX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 478.8x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 361.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHEMOCENTRYX INC, please visit www.chemocentryx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.